Why are Immuno-Oncology compounds different?
Why are Immuno-Oncology compounds different?
Engineering of polymeric nanoparticles for medical applications
Making sense of the expanding armoury of treatment options for the less fit CLL patient
Biobanks, rare tumours and the importance of collecting primary material
Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumours
The molecular basis of cancer
The role of molecular pathways in therapeutic response and outcomes in breast cancer
Traditional and personalised models of therapy in gastrointestinal and endocrine tumours: the role of histological and clinical markers
Future perspectives: realising the potential of personalised healthcare in gynaecological cancer
The revolution in personalised healthcare: Towards improved outcomes in oncology: Conclusion and Summary
Advances in geriatric, medical oncology
Results from the SIOG task force on geriatric assessment